Archive

Genitourinary Cancers Symposium Daily News Archive

The Genitourinary Cancers Symposium Daily News is the official news source for the Genitourinary Cancers Symposium, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.


February 9, 2017

Dr. Michael Schweizer discusses why he continues to attend the GU Cancers Symposium and the sessions he’s looking forward to attending.

Read more

February 9, 2017

Dr. David J. McConkey will discuss immunology in bladder cancer during the urothelial carcinoma keynote lecture.

Read more

February 9, 2017

Dr. Charles G. Drake will deliver the prostate cancer keynote lecture.

Read more

February 9, 2017

The United States and United Kingdom treat prostate cancer differently when it comes to active surveillance. Read why.

Read more

February 9, 2017

Dr. Neha Vapiwala discusses the role of whole-body MRI in prostate cancer staging.

Read more

February 9, 2017

In urothelial carcinoma, is there a difference in efficacy or safety among agents that target PD-1 vs. agents that target PD-L1? 

Read more
February 9, 2017

ASCO’s Virtual Mentoring Program matches international, early-career members with seasoned oncology professionals who connect via phone or social media to enhance professional development and an understanding of global oncology practices.

Read more

February 9, 2017

In bladder cancer, what do you recommend for second-line treatment once disease progresses after combination gemcitabine/cisplatin?

Read more

February 9, 2017

Dr. Asif Muneer will discuss immunotherapies for advanced penile cancer during the penile, urethral, and testicular cancers year in review lecture.

Read more

February 9, 2017

Dr. Neha Vapiwala highlights the findings from the ProtecT trial, which compared surgery, radiation, and active surveillance for the treatment of localized prostate cancer.

Read more
February 9, 2017

Experts discuss the current imaging techniques for staging and managing muscle-invasive and metastatic bladder cancer, as well as other promising imaging options currently being studied. 

Read more
February 9, 2017

Dr. Jeanny B. Aragon-Ching discusses the pros and cons of new treatments for patients with oligometastatic prostate cancer.

Read more
February 9, 2017

Active surveillance has emerged as a therapeutic strategy for small renal masses in patients for whom the risks of surgical treatment may outweigh the oncologic benefits of resection.

Read more
February 9, 2017

Experts discuss the complex relationship between androgen signaling and hypoxia-driven signaling pathways in prostate cancer and how to tailor chemotherapy, radiotherapy, and immunotherapy to treat this disease.

Read more

February 9, 2017

Pulitzer Prize-nominated journalist Howard Wolinsky discusses his personal experience with active surveillance for prostate cancer.

Read more

February 9, 2017

Dr. Ashish M. Kamat (pictured) and Dr. Matthew T. Campbell discuss the state of immunotherapeutics and targeted therapy and the potential impact of biomarkers and molecular subtyping in personalizing therapy for urothelial cancer.

Read more
February 9, 2017

Patients with non–clear cell RCC represent a heterogeneous group of distinct disease entities. These patients have historically been underrepresented in clinical trials, and there is a need for further prospective studies exploring current and novel agents in this patient population. 

Read more

January 19, 2016

The 2016 Genitourinary Cancers Symposium brought together 3,300 attendees to discuss the latest advances in the treatment of GU malignancies, including treatment delivery; discoveries in immunotherapy; and the exploration of biomarkers, genomic analysis, and DNA profiling.

Read more

January 10, 2016

Preplanned subgroup analyses of CheckMate 025 data show that the survival and response benefits observed with nivolumab in the overall population also apply across a wide variety of patient subgroups, supporting its use as a second-line agent for RCC.

Read more

January 10, 2016

Dr. Bernard J. Escudier presented updated PFS METEOR trial data, which show that patients benefit more from cabozantinib than everolimus as second-line treatment, regardless of risk status, disease burden, sites of metastases, and prior treatment (Abstract 499).

Read more